The company’s leading product, INTERCEPT™ Blood System, is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens, including viruses, bacteria, and parasites, that may be present in donated blood components. Cerus Corporation’s INTERCEPT™ Blood System is based on a proprietary technology that uses a photochemical process to inactivate pathogens in donated blood components. This technology has been proven to be effective in minimizing the risk of transfusion-transmitted infections and has been adopted by several Countries and blood centers worldwide. Cerus Corporation’s INTERCEPT™ Blood System includes the INTERCEPT™ Plasma and the INTERCEPT™ Platelets systems, designed to inactivate pathogens in plasma and platelets, respectively.

Cerus Corporation’s mission is to improve global public health by providing safer blood transfusion options to patients in need.